Effects of Edaravone and Dexborneol Combined with Butylphthalide on Serum Matrix Metalloproteinases,Neurologic Injury Factors and Endothelial Function in Patients with Cerebral Infarction
Objective:To investigate the clinical efficacy of edaravone and dexborneol combined with butylphthalide in the treatment of patients with cerebral infarction and its effects on serum matrix metalloproteinases(MMPs),neurologic injury factors and endothelial function.Methods:A total of 408 patients with cerebral infarction treated in a hospital from July 2022 to June 2023 were selected and assigned to the control group and observation group by random number table method,with 204 patients in each group.Both groups were treated with conventional treatment such as oxygen inhalation,protecting cranial nerve,relieving brain edema,improving microcirculation,reducing intracranial pressure and maintaining fluid and electrolyte balance.The control group was additionally treated with butylphthalide and sodium chloride injection,whereas the observation group was treated with edaravone and dexborneol concentrated solution for injection in addition to the treatment given in the control group,and both groups were treated for 14 days.The levels of MMPs[matrix metalloproteinase-2(MMP-2),matrix metalloproteinase-9(MMP-9)],neurologic injury factors[brain-derived neurotrophic factor(BDNF),S100β,intercellular adhesion molecule-1(ICAM-1)],endothelial function indexes[endothelin-1(ET-1),nitric oxide(NO)],clinical response and adverse reactions were compared between the two groups.Results:After treatment,the serum levels of MMP-2 and MMP-9 were decreased in both groups(P<0.05),and were lower in the observation group than those in the control group(P<0.05).The serum BDNF level was increased in both groups(P<0.05),and was higher in the observation group than that in the control group(P<0.05).The serum levels of S100β and ICAM-1 were decreased in both groups(P<0.05),and were lower in the observation group than those in the control group(P<0.05).The serum ET-1 level was decreased in both groups(P<0.05),and was lower in the observation group than that in the control group(P<0.05).The serum NO level was increased in both groups(P<0.05),and was higher in the observation group than that in the control group(P<0.05).The total response rate in the observation group(96.57%)was higher than that in the control group(82.35%,P<0.05).No statistically significant difference in the incidence of adverse reactions was observed between the two groups(P>0.05).Conclusion:Edaravone and dexborneol combined with butylphthalide has good clinical efficacy in the treatment of patients with cerebral infarction as it can effectively inhibit the production of MMPs,and improve the levels of neurologic injury factors and endothelial function indexes,without additional risks of adverse reactions.
edaravone and dexborneolcerebral infarctionmatrix metalloproteinasesneurologic injury factorsendothelial function
国家科技期刊平台
NSTL
万方数据
